Safety of TKI258 in Advanced/Metastatic Melanoma Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

47 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is an open-label, dose-escalating study to delineate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TKI258. Pharmacokinetics and pharmacodynamics will be performed on all subjects. The eligible subject population consists of subjects who have been diagnosed with locally advanced or metastatic melanoma that is refractory to standard therapy or for which no curative standard therapy exists.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Malignancies

NCT00669097

Advanced Solid Malignancies

COMPLETED PHASE1

Bioequivalence of 2 Formulations of TKI258 in Patients With Advanced Solid Tumors

NCT01421004

Advanced Solid Tumors Excluding Breast Cancer

COMPLETED PHASE1

Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK2126458 and GSK1120212 Combination Therapy in Subjects With Advanced Solid Tumors.

NCT01248858

Cancer

TERMINATED PHASE1

Pilot Trial of "Chemo-Switch" Regimen to Treat Advanced Melanoma

NCT00673361

Melanoma

TERMINATED PHASE2

Saracatinib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

NCT00669019

Recurrent Melanoma Stage IIA Melanoma Stage IIB Melanoma +2 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TKI258

Group Type EXPERIMENTAL

TKI258

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TKI258

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed diagnosis of locally advanced or metastatic melanoma (American Joint Committee on Cancer \[AJCC\] stage IIIB, IIIC or IV) that is refractory to standard therapy or for which no curative standard therapy exists.
* Measurable disease
* Must be eighteen years of age or older
* Must meet baseline laboratory requirements
* ECOG performance status 0 or 1
* Adults of reproductive potential must agree to use effective contraception or be sterile

Exclusion Criteria

* Concurrent therapy with any other investigational agent
* Uncontrolled central nervous system metastases
* Impaired cardiac function or clinically significant cardiac disease
* Received

* chemotherapy, targeted therapy or monoclonal antibody therapy ≤4 weeks
* biological therapy or immunotherapy (therapeutic or diagnostic) ≤2 weeks
* an investigational agent (therapeutic or diagnostic) ≤4 weeks prior to starting study drug or has not recovered from side effects of such therapy
* Received any hematopoietic colony-stimulating factor (e.g., G-CSF, GM-CSF) ≤ 2 weeks prior to starting study drug. Erythropoietin is allowed.
* Has undergone major surgery ≤ 2 weeks prior to starting study drug or has not recovered from side effects of such surgery.
* Malabsorption syndrome or uncontrolled gastrointestinal symptoms such as nausea, diarrhea, vomiting
* Pregnant or breast feeding women
* History of another primary malignancy that is currently clinically significant or currently requires active intervention.
* Chronic anticoagulation therapy with full strength aspirin, Coumadin, or heparin.
* History of thromboembolic or cerebrovascular events within the last 12 months.
* History of rectal bleeding, bloody vomit, or spitting up blood within the last 3 months.
* Known diagnosis of HIV infection (HIV testing is not mandatory)
* Use of ketoconazole, erythromycin, carbamazepine, phenobarbital, phenytoin, rifampin, St. John's wort and quinidine is prohibited.
* Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study-drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, make the patient inappropriate for this study

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No